Training events and courses
CALIT
Paul BORM || 28 October || Visionary Symposium on Nano-Bio-Cogno
Nanoparticles Nanoparticles in drug delivery: a potential benchmark for all nanomaterials?
Paul J.A. Borm, MagnaMedics Diagnostics BV, Geleen and Centre of Expertise in Life Sciences, Zuyd University for Applied Sciences, Heerlen (NL)
Abstract
Major opportunities of nanopartilces are provided by applications in Life Sciences such as drug delivery, imaging and point-of-care diagnostics. Also in other industrial sectors, nano seems to be enabling product improvement, innovation and sustainable production. Nevertheless the nanoparticle-issue is persistent and also used to create noise in the nanodebate. Nevertheless, the concern is high and driven by scarce new data on exposure and toxicity of nanoparticles.
The debate is driven by three major concerns, i.e. (1) the health effects caused by ultrafine particles in ambient particulate matter (PM), 2) the surface driven effect of nanoparticles in the lungs, and 3) the theoretical concept that if material properties change than toxicological properties will be affected.
In drug delivery many nanopartciulate materials and shapes are being explored for carrying active substances to target sites, but little attention has been payed sofar to use this data for benchmarking of nanoparticle toxicology. During his presentation the author will give some examples of existing studies and try to derive some directions for the future, by discriminating key-factors allowing NP into the good, bad and ugly.
References
Borm PJA and Berube D. A nanotale of opportunities, uncertainties and risks. NanoToday, 2008. Borm PJA and Muller-Schulte. Nanoparticles in drug delivery and environmental exposure: same size, same risk? Nanomedicine, 2006)
CV
Since 2003, Professor Dr. Paul J.A. Borm has been with the Centre of Expertise in Life Sciences (CEL) in Heerlen, The Netherlands. He earned his Ph.D. in 1984 from the University of Utrecht in The Netherlands. From 1998-2003, he was head of section, Particle Research, Institute for Environmental and Medical Research, University of Dusseldorf, Germany, in 2001. His previous positions include, associate professor in Toxicology and Occupational Hygiene, University of Maastricht, Dept of Health Risk Analysis & Toxicology (1988-1998), and director of ABK Consultancies Maastricht BV, Consultancy in Occupational Health (1989-1992). From 1991-1997, he was head of the Toxicology Division; Nutrition, Toxicology and Environmental Research Institute, Maastricht, The Netherlands. Professor Borm is a member of the German MAK-commission and of the Dutch Evaluation committee on Occupational Substances (DECOS), and the special board on risks and opportunities of Nanomaterials.
He has been an invited member of expert groups such as IARC (1996), ILSI (1998) and ECVAM (1997). He was the (co) organizer of a large series of international meetings, including the 7th International Meeting on Particle Toxicology, Maastricht (1999), the DFG workshop on particle carcinogenicity, Munich (2000), ECETOC meeting on Nanomaterials (2005) and Cells at Work III, a Life Science to Business event in Maastricht (2005). He is an editorial board member in Human Experimental Toxicology and Inhalation Toxicology and co-editor of Particle and Fibre Toxicology, and has done peer reviews for many journals. Dr. Borm has published more than 160 peer reviewed publications, and has been the recipient of millions of dollars in extramural research support from various government, EU and private sources. His current research interests relate to the effects of (nano) particles on various extrapulmonary systems such as vascular tissue, heart, blood and brain. His business activities through BLiS2B BV include the support of development of drug delivery and diagnostic systems using micro- and nanoparticles.